Research ArticleHuman Studies
Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma
John E. Bayouth, Daniel J. Macey, Leela P. Kasi, Joseph R. Garlich, Kenneth McMillan, Meletios A. Dimopoulos and Richard E. Champlin
Journal of Nuclear Medicine May 1995, 36 (5) 730-737;
John E. Bayouth
Daniel J. Macey
Leela P. Kasi
Joseph R. Garlich
Kenneth McMillan
Meletios A. Dimopoulos


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma
John E. Bayouth, Daniel J. Macey, Leela P. Kasi, Joseph R. Garlich, Kenneth McMillan, Meletios A. Dimopoulos, Richard E. Champlin
Journal of Nuclear Medicine May 1995, 36 (5) 730-737;
Jump to section
Related Articles
- No related articles found.
Cited By...
- 166Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal Targeted Radiotherapy
- 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
- High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation
- Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial